Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.66 USD
Change Today -0.01 / -0.37%
Volume 54.8K
CLSN On Other Exchanges
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

celsion corp (CLSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/14 - $3.73
52 Week Low
01/28/15 - $2.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELSION CORP (CLSN)

celsion corp (CLSN) Related Bloomberg News

View More Bloomberg News

celsion corp (CLSN) Related Businessweek News

No Related Businessweek News Found

celsion corp (CLSN) Details

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

28 Employees
Last Reported Date: 03/12/15
Founded in 1982

celsion corp (CLSN) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $434.1K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $275.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $328.5K
Compensation as of Fiscal Year 2013.

celsion corp (CLSN) Key Developments

Celsion Corp. Announces Condensed Earnings Results for the Year Ended December 31, 2014

Celsion Corp. announced condensed earnings results for the year ended December 31, 2014. For the year, licensing revenue was $500,000 against $500,000 a year ago. Net loss from operations was $25,494,000 against $8,251,000 a year ago. Net loss attributable to common shareholders was $25,494,000 against $12,852,000 a year ago. Basic and diluted net loss per common share was $1.38 against $0.95 a year ago. Net cash used in operations was $21.4 million compared to $9.5 million in the prior year.

Celsion Corp. to Report Q4, 2014 Results on Mar 12, 2015

Celsion Corp. announced that they will report Q4, 2014 results at 11:00 AM, US Eastern Standard Time on Mar 12, 2015

Celsion Corp., Q4 2014 Earnings Call, Mar 12, 2015

Celsion Corp., Q4 2014 Earnings Call, Mar 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLSN:US $2.66 USD -0.01

CLSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Medifocus Inc C$0.04 CAD +0.005
Perseon Corp $0.36 USD -0.0649
View Industry Companies

Industry Analysis


Industry Average

Valuation CLSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 107.0x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSION CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at